Khadijah M. Silver • February 11, 2016
The fifth and final story in our series on escalating U.S. drug prices looks at the impact that presidential politics will have on the pharma industry.
John Bilton • February 11, 2016
The greenback’s recent travails are a sign of international economic distress rather than U.S. feebleness. A weaker dollar would help.
Andrew Barber • February 11, 2016
Swedish kroner falls on news; British gilts briefly hit all-time low; Societe Generale earnings disappoint; Puerto Rico approves utility restructuring; gold surges.
Gerrard Cowan • February 10, 2016
Inflows into European ETFs hit a record high in 2015 on recovery hopes and attractive valuations.
Jeff Ostrowski • February 10, 2016
Investors and market observers disagree on whether prices will drop — and on the severity of a correction if there is one.
Andrew Barber • February 10, 2016
Global bond markets move to tax savers; Trump, Sanders victorious in New Hampshire; U.S. food services giant files for IPO; Deutsche said to be buying back debt.
Tom Buerkle • February 10, 2016
CEO Martin Gilbert is diversifying the U.K. fund manager and keeping faith with his people and investment process.
Allen T. Cheng • February 09, 2016
In the Year of the Monkey, cash-filled envelopes to officials have given way to cakes and fruit — some stuffed with gold or jewels.
Dan Weil • February 09, 2016
Sagging commodities prices and China’s woes have weighed on the greenback. Interest rate differentials might kick the dollar back in gear.
Andrew Barber • February 09, 2016
Japanese stocks sell off as yen rebounds; Sanofi reports drop in profits; New Hampshire votes in U.S. presidential primary.
© 2016 Institutional Investor LLC. All material subject to strictly enforced copyright laws.
Please read our
Term and Conditions and